Biota Pharmaceuticals Inc  

(Public, NASDAQ:BOTA)   Watch this stock  
Find more results for BOTA
-0.05 (-3.65%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.28 - 1.39
52 week 1.23 - 2.67
Open 1.39
Vol / Avg. 10,422.00/61,316.00
Mkt cap 49.14M
P/E     -
Div/yield     -
EPS -0.50
Shares 38.64M
Beta 0.85
Inst. own 34%
May 5, 2016
Q3 2016 Biota Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 5, 2016
Q2 2016 Biota Pharmaceuticals Inc Earnings Release
Feb 5, 2016
Q2 2016 Biota Pharmaceuticals Inc Earnings Call
Jan 11, 2016
Biota Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 15, 2015
Biota Pharmaceuticals Inc at Guggenheim Boston Healthcare Conference
Nov 18, 2015
Biota Pharmaceuticals Inc at Stifel Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin -388.24% -77.64%
Operating margin -394.12% -79.27%
EBITD margin - -88.62%
Return on average assets -35.20% -19.75%
Return on average equity -39.81% -24.42%
Employees 19 -
CDP Score - -


2500 Northwinds Pkwy Ste 100
ALPHARETTA, GA 30009-2248
United States - Map
+1-301-7703099 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biota Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. The Company has around four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus (HRV) infections in moderate-to-severe asthmatics that is being evaluated in its ongoing Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA585, an oral fusion (F) protein inhibitor in Phase I development for the treatment of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate, a one-time, inhaled treatment in Phase II development for influenza A and B infections. The Company also has preclinical RSV non-fusion inhibitor program.

Officers and directors

Mark P. Colonnese Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Russell H. Plumb Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Joseph M. Patti Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Armando Anido Independent Director
Age: 57
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael W. Dunne M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
John P. Richard Independent Director
Age: 58
Bio & Compensation  - Reuters